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Abstract: The cytotoxic and antiproliferative properties of many natural sesquiterpene-
quinones and -hydroquinones from sponges offer promising opportunities for the 
development of new drugs. A review dealing with different  strategies for  obtaining 
bioactive terpenyl quinones/hydroquinones is presented. The different synthetic approches 
for the preparation of the most relevant quinones/hydroquinones are described. 
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1. Introduction 
The chemical substances from plants and animals have been and remain to be an important source 
of drugs and products used in food products, cosmetics and agriculture, amongst other fields. Natural 
compounds offer an enormous structural diversity and in some cases, a big biological power and thus it 
is unlikely that the chemistry of synthesis can replace cellular biochemistry as the source of new 
compound. These observations, in addition to the enormous biodiversity of the planet (plants, sea and 
microorganisms), which is in a lot of cases inexplored, point to natural compounds as a promising 
source of drugs [1–45]. 
Natural products have been a rich source of agents of value to medicine. More than half of the 
currently available drugs are natural compounds or are related to them, and in the case of cancer this 
proportion surpasses 60%  [4,8]. This situation is accompanied by increasing interest from drug 
companies and institutions devoted to the search for new drugs  [46,47].  Additionally, many new 
natural compounds of diverse structures have been considered prototypes, leads or heads of series and 
their later structural modification has afforded compounds with pharmacological activity and 
extraordinary therapeutic possibilities [11,22,25,26,48]. 
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The  research  in natural compounds, which is continually expanding and is of enormous   
interest, explores  new  compounds  coming  from  different sources, among which  the sea  could be 
considered as an almost infinite source of natural resources, some of which have important therapeutic 
potential [49–126]. The discovery of drugs from marine natural products has enjoyed a renaissance in 
the past few years. Ziconotide (Prialt
®; Elan Pharmaceuticals), a peptide originally discovered in a 
tropicalcone snail, was the first marine-derived compound to be approved in the United States in 
December 2004 for the treatment of pain [127]. Combination of ziconotide and morphine allows safe 
and rapid control of oral opioid-refractary malignant pain [128].  In October 2007, trabectedin 
(Yondelis
®; PharmaMar) became the first marine anticancer drug to be approved in the European 
Union.  Trabectedine is an intravenous antineoplastic agent originally derived from tne Caribbean 
marine tunicate Ecteinascidia turbinata and now produced synthetically [129]. Trabectedine shows 
variable levels of activity against several types of solid tumor including soft tissue sarcoma, ovarian 
cancer, breast, melanoma, non small lung cancer, prostate and endometrial cancer [130–132]. The drug 
is especially active in leiomyosarcoma and liposarcoma and is a therapeutic option in the palliative 
approach to the metastatic uterine leiomyosarcoma patient [133]. Eribulin mesylate (E7389), designed 
by the Japanese laboratory Eisai (Eisai Research Institute, Andover, MA, USA), shows antitumor 
properties for the treatment of breast cancer [134]. This is a synthetic analogue of the natural product 
halichondrin B, isolated from Halichondria okadai (Lissodendoryx sp.), a marine sponge commonly 
found in Japanese seas; its antitumor activity was discovered in 1986. Eribulin binds to the vinca 
domain of tubulin and inhibits the polymerization of tubulin and theassembly of microtubules, 
resulting in the inhibition of mitotic spindle assembly, the induction of cell cycle arrest at G2/M, and, 
potentially, tumor regression. Eribulin mesylate is now in phase II clinical  trials and is active in 
metastatic or locally advanced breast cancer [135–138]. 
Excellent reviews on natural compounds of marine origin have  been published [49–126]  that 
explore the taxonomy, structural elucidation, role of databases, biosynthetic studies, biomedical 
potential, synthesis and the technologies necessary for advancing bioactive marine natural product lead 
compounds into actual pharmaceuticals.  Amongst these, the recently published review by   
Fattorusso et al. [124] particularly stands out. 
Among  the natural compounds that are receiving an increasing interest we  can find the 
terpenylpurines and the terpenilquinones from  marine sources [139,140]. Particularly, the 
terpenylquinones constitute an interesting group of marine natural product [141–143] for which a wide 
variety of biological activities have been described, including anti-inflamatory, antifungal, anti-HIV 
and most often antitumor activities [144,145].  
The cytotoxic and antiproliferative properties of many natural sesquiterpene quinones  and 
hydroquinones from sponges of the order Dictyoceratida [71,76,140,144] such as avarol 1, avarone 2, 
illimaquinone  3, nakijiquinone  4  and  bolinaquinone  5  (Figure  1),  amog  others,  offer promising 
opportunities for the development of new antitumor agents [144,145]. This has sparked interest in the 
chemical composition and cytotoxicity of a large number of marine species that contain metabolites 
with hybrid structures between terpenes and quinones/hydroquinones [76,140,141,146–150]. Mar. Drugs 2012, 10                
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Figure 1. Some examples of bioactive terpenequinones/hydroquinones. 
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Avarol  1  and avarone  2  are the most representative compounds  of bioactive terpenequinones.   
In addition to the above-mentioned  pharmacological  properties,  two monophenyl thioavarol 
derivatives have recently been described as lacking cytotoxicity, which could point to promising UVB 
photoprotective  agents through the  potent inhibition of NF-kappaB activation [151]  with a mild 
antioxidant pharmacological profile. Various formulations with high avarol 1 content have been used 
for the prevention and treatment of psoriasis, dermatitis, skin cancer, tumors in the gastrointestinal 
tract, urinary tract and viral infection [152]. 
It is also  important to note  the  antituberculosis  and antimalarial activities of puupehenone  6 
[93,153,154],  the cardiotonic activity of xestoquinone  7  [155],  the antifungal activity of several 
nakijiquinones 4 [156] and the antiinfective activity of aureol derivatives 9 [157]. 
Sesquiterpenequinones represent a substance class with increasing pharmacological interest [140]. 
New developments and new discoveries in the field of terpenequinones continually occur. Recently, 
neopetrosiquinones A 10 and B 11 (Figure 2), sesquiterpene benzoquinones have been isolated from 
the deep-water sponge Neopetrosia cf. proxima, of the Petrosiidae family [158]. Neopetrosiquinones A 
10 and B 11 inhibit the in vitro proliferation of the DLD-1 human colorectal adenocarcinoma cell line 
with IC50 values of 3.7 and 9.8 μM, respectively, and the PANC-1 human pancreatic carcinoma cell 
line with IC50 values of 6.1 and 13.8 μM, respectively. Neopetrosiquinone A also inhibited the in vitro 
proliferation of the AsPC-1 human pancreatic carcinoma cell line with an IC50 value of 6.1 μM. The 
compounds are structurally related to known terpene quinine xestoquinone 7. This research is part of 
the program to identify novel marine natural products with therapeutic properties from a library of 
extracts of the Harbor Branch Oceanographic Institute (HBOI) [158]. Mar. Drugs 2012, 10                
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Figure 2. Neopetrosiquinones A 10 and B 11. 
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Regarding the mechanism of action of terpenylquinones, the accumulated data about the biological 
activity of quinone moieties suggest redox processes and/or Michael-type addition-elimination 
reactions [144]. Their cytotoxicity has been explained in terms of their ability to undergo redox cycling 
and the generation of reactive oxygen species, which would damage tumor cells [159–161]. 
NADH/NAD
+ dehydrogenase reduction of the several terpenylnaphthoquinones increases the rate of 
oxygen consumption, such rates being higher for quinones with more positive redox potentials. In this 
process, reactive oxygen species are formed in small amounts, which also correlate with the quinine 
redox potential. Semiquinone derivatives of these quinones are generated under anaerobic conditions 
and in the presence of NADH/NAD
+  dehydrogenase. Since this enzymatic system is found in 
mitochondria, a possible pathway in the cytotoxic activity of these terpenylnaphthoquinones could be 
by  interference with or the inhibition of mitochondrial respiration, as reported for other 
naphthoquinone derivatives, in addition to free radical degradation [162,163]. The results obtained 
with avarol 1 and avarone 2 supported the mechanism of antitumor action via the reactive oxygen 
radicals [164,165] but there were also indications of the relevance of arylation of biomolecules, such as 
proteins [144,166,167]. 
Regarding such terpenequinone structures, many studies have been published addressing the isolation, 
structural elucidation, activity and mechanisms of action of the compounds [140,143,144,146,147,160]. 
We present in this review a compilation of the different synthetic approches for the preparation of the 
most relevant compounds. 
2. Synthetic Approches Terpenylquinone/Hydroquinone 
The synthesis of marine natural products has been widely researched and published in excellent 
reviews [3,168–183], and is of particular interest in the case of compounds that have some kind of 
biological or therapeutic activity. The two major obstacles to advancing a natural product lead into 
drug development are compound supply and adequate structural elucidation. One must not underestimate 
how much material may be needed. Even the  most straightforward courses of pre-clinical studies 
require hundreds of grams of highly consistent well-characterized product, which represents a major 
hurdle for natural products derived from non-renewable sources [3]. Therefore, it is of interest to 
consider the relative role of chemical synthesis in the structure elucidation. Moreover, in the case of 
revision of relative and absolute configuration, total synthesis is a proven partner for natural product 
structure elucidation for marine, as well as terrestrial species [169]. Structural misassignments continue Mar. Drugs 2012, 10                
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to be made even for recently reported marine natural products, and thus, it seems that the increasingly 
high-field magnets and sensitive  probes do not necessarily attenuate the rate of structural 
misassignments.  Rather, they permit the attempted structure elucidation  of increasingly limited 
quantities of minor components from natural products extracts, as well as larger molecules of greater 
structural complexity. Therefore, total synthesis of natural products will surely continue to be central 
to the confirmation of the structure of natural products, as well as providing material for biological 
testing towards pharmaceutical development, and  investigations of biosynthetic pathways [169]. 
Advances in total synthesis, especially function-oriented syntheses,  biosynthetic technologies and 
genomic research offer new strategies for the medicinal chemical optimization of biologically active 
secondary metabolites as sources of novel drug leads [3]. 
In  the case of  biologically active  terpenoquinones,  the  limited quantities components  from the 
natural sources and the structural complexity  are the main problems in  continuining the clinical 
studies. Most of these terpenoquinones are characterised by possessing a quinone fragment attached to 
a terpenoid, which usually includes a decaline core, mostly with a drimane or rearranged drimane 
skeleton. Most sesquiterpenequinone/hydroquinones have been isolated from sponges, although some 
of them have been described from brown algae [74] and fungi [184]. The initial extract of the natural 
material usually consists of a complex mixture after fractionation. It may contain small quantities of 
bioactive substances, often as a mixture with structurally related molecules. The initial concentration 
of an interesting compound may be too low to be effectively tested in some biological and 
pharmacological assays. Thus, compounds have become attractive to carry out its total synthesis and 
obtaining of derivatives to improve the biological properties of natural compounds. Consequently, the 
development of these marine natural products is highly desirable and worthwhile from the viewpoint 
of medicinal chemistry and pharmaceuticals.  
In  the  present paper, the most interesting  strategies  addressed in the  total synthesis of 
sesquiterpenilquinones  by  terpenic  structure coupling  to an aromatic ring  have been reviewed.  
In general, the strategies employed in the total synthesis of sesquiterpenilquinones, are as follows: 
  Diels-Alder cycloaddition reaction. 
  Coupling of the aldehydes with lithiated hydroquinone ether. 
  Radical decarboxylation and quinone addition reaction 
  Grignard reagent conjugated addition to α,β-unsaturated carbonyl group. 
  Reductive alkylation of enones. 
  Cross-coupling reaction. 
  Furylation of quinones. 
  Furan polyene cationic cyclization. 
In addition, the application of cell culture for the production of bioactive compounds from sponges 
is a promising way to utilize the bioactive potential of marine terpenoquinones sources. 
3. Diels-Alder Cycloaddition Reaction 
The Diels-Alder cycloaddition reaction continues to fuel the imaginations of synthetic chemists 
engaged in the assembly of complex molecular structures, in particular biologically significant   Mar. Drugs 2012, 10                
 
363 
natural products and provide rich opportunities for the rapid and selective generation of molecular 
complexity [185].  
Mamanuthaquinone  12  is a cytotoxic metabolite collected in the Fiji islands from  
Fasciospongia sp. [186]. In the first total synthesis of (±)-mamanuthaquinone 12 (Scheme 1) [187] an 
exothermic  Diels-Alder  reaction  have been used as main reaction, giving the  decalin  system  that 
already contains the aromatic moiety. The Diels-Alder reaction proceeded via an exo transition state, 
favored by the steric hindrance between the aromatic ring of 13 and a methyl of the cyclohexene 14. 
This exo approach mode reached the desired stereochemistry for mamanuthaquinone 12. With the 
configuration  of the three  stereocenters  established, the  cycloadduct  15  was treated with  LiAlH4 
yielding the reduction of the ketone and the demethylation of one methoxyl in the ortho position: 
diastereomers 16a,b. The acetylated derivative 17a,b which Li/NH3 gave deoxygenation at C-15 and 
was acetylated in alcohol C-21 leading to 19. Finally, oxidation with CAN, followed by saponification 
of the acetate at C-21 yielded (±)-mamanutaquinone 12. 
Scheme 1. Synthesis of (±)-mamanuthaquinone 12. 
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Starting from  natural  terpenes,  various approaches  to  terpenoquinones  analogues  have  been 
reported.  The terpene  contributes  the  decalin  part  that attaches  via  Diels-Alder  cycloaddition  to 
commercial quinones. Thus, some diterpenylquinones/hydroquinones have been prepared through a 
Diels-Alder cycloaddition  between myrceocommunic acid 20  and  p-benzoquinone  21  or 
naphthoquinone 22 [149,159,188] (Scheme 2). The natural labdane acid used as starting material was 
isolated from berries of Juniperus oxycedrus. In order to optimise the synthesis of cycloadduct, two 
Diels-Alder procedures were considered, one in ethereal solution using BF3·Et2O as a catalyst and the Mar. Drugs 2012, 10                
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other under Mw irradiation in the absence of solvent. Although the Mw irradiation has the advantage 
of shortening reaction time, this procedure needs an excess of quinone that impeeds the purification of 
the final product. Several derivatives of cycloadducts 23 and 29 were evaluated in vitro for determinig 
their cytotoxicity against the human cell lines HT-29 (colon carcinoma), A-549 (lung carcinoma) and 
MEL-28 (malignant melanoma). Some of them were cytotoxic with IC50 values under the μM level. 
Scheme 2.  Diels-Alder cycloaddition between myrceocummunic acid and   
p-benzoquinone/naphthoquinone. 
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Puupehenones belong to an important class of marine terpenequinone metabolites from Hyrtios sp. 
and other marine sponges [189–192], which are constructed from drimane and polyphenolic moieties. 
Puupehenones exhibit a wide variety of biological activity including angiogenesis inhibition [193]. 
The  Diels Alder cycloaddition approach has  been used to synthesize  puupehenone related   
metabolites  [194,195].  Utilizing this, the potent angiogenesis inhibitor 8-epipuupehedione  33  was 
synthesized from sclareol oxide  30, via ent-chromazonarol  32  (Scheme 3); in this case, the 
methodologie used prevents the obtention of the 8-epimer which is formed when the electrophilic 
cyclization methodology  is utilized [196,197].  Microwave-assisted Diels-Alder reaction of   
1,3,3-trimethyl-2-vinyl-1-cyclohexene 34 with chromones 35 (Scheme 4) is an expeditious approach to 
analogues of the puupehenone group 36 of marine diterpenoids [198]. 
Scheme 3. Diels-Alder cyclooaddition approach to puupehenone-related metabolites. 
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Scheme 4. Microwave-assisted Diels-Alder reaction of 1,3,3-trimethyl-2-vinyl-1-cyclohexene 
with chromones. 
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The marine (−)-cyclozonarone  37  has been isolated from the Pacific brown algae Dictyopteris 
undulata and possesses a potent feeding-deterrent activity towards young abalones [199]. The total 
synthesis was achieved starting from  albicanol  38  (Scheme  5)  [200]. Elimination of water led to   
drima-(8,12)(9,11)-diene 39, which reacted in the key step of the synthesis, a Diels-Alder reaction, 
with benzoquinone. Further oxidation led to 37. Mar. Drugs 2012, 10                
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Scheme 5. Synthesis of (−)-cyclozonarone 37. 
 
The Diels-Alder cycloaddition between two polygodial-derived dienes  41  and  43  and simple 
quinones 42 and 22 yield substituted naphthaquinones 40 and anthraquinones 44, some of them with  
in vitro trypanocide activity (Scheme 6) [201]. 
Scheme 6. Diels-Alder reaction between polygodial-derived dienes and simple quinones. 
 
Halenaquinone  8,  a pentacyclic polyketide isolated from Xestospongia  sp.  [202], has been 
synthesized both through a strategy based on an intramolecular inverse-electron-demand Diels-Alder 
reaction and an intramolecular Heck cyclization [203,204]. 
4. Coupling of the Aldehydes with Lithiated Hydroquinone Ethers 
This strategy is an efficient and general way of accessing drimane-type sequiterpenequinones. The 
strategy consists on the coupling of an aldehyde as terpene precursor and a lithium anion which carries 
the  quinone  structure.  The five marine natural products yahazunol 45, zonarone 46, zonarol 47, 
isozonarone  48  and isozonarol 49  have been synthesised starting from (+)-albicanic acid   
(+)-51 [205,206]. Yahazunol 45, zonarone 46 and zonarol 47 have been obtained from the East Pacific 
brown algae Dictyopteris undulata Okamura. Isozonarone 48 and isozonarol 49 have been isolated Mar. Drugs 2012, 10                
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from the same species collected in the Gulf of California [207]. These compound present fungitoxic, 
anti-inflammatory activities and locks the MCF-7 cells initially in the mitose phase (G2/M-phase) and 
induce apoptosis, also blocks the synthesis phase with replication of DNA (S-phase) [72,142,207,208]. 
Scheme 7. Retrosynthesis of yahazunol 45 and isozonarone 48. 
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Scheme 8. Total synthesis of zonarol 47, isozonarol 49, zonarone 46 and isozonarone 48. 
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The synthesis of the marine natural products zonarone 46 and isozonarone 48 was achieved via  
(+)-albicanic acid 51, a sesquiterpene of the drimane type (Scheme 7). Coupling of the appropiate 
drimane-synthon with lithiated hydroquinone ethers led to sesquiterpene arenes, which were further 
modified to the target molecules. Stereoselective epoxidation followed by regioselective opening of 
the oxirane ring yielded yahazunol [205,206]. The key step of the synthesis (Scheme 8) was the 
coupling of the sesquiterpene part with the lithiated arene unit. The starting quiral aldehydes   
(+)-albicanal ((+)-52) and (−)-drim-7-en-11-al (−)-50 were obtained from (+)-albicanic acid (+)-51. 
This chiral synthon was prepared starting from β-ionone via a known route [209]. The di-THP-ether of 
hydroquine was  lithiated with sec-butyllithium and added (+)-albicanal  52, respectively   
(−)-drim-7-en-11-al 50, to formed lithium organyl. The reaction afforded the benzyl alcohol 54a,b and 
56a,b, as coupling products as mixture of diastereoisomers. Removal of the hydroxyl group led to the 
deoxygenated species zonarol-di-THP-ether  55  and isozonarol-di-THP-ether  57, respectively. 
Desprotection in presence of oxalic acid [205] gave zonarol 47 and isozonarol 49. Optimized oxidation 
of zonarol and isozonarol with cerium (IV) ammonium nitrate (CAN) yielded the sesquiterpenequinone 
zonarone 46 and isozonarone 48. 
The synthesis of the marine sesquiterpene quinones (+)-hyatellaquinone 58 and spongiaquinone 60 
was respectively achieved starting from the sesquiterpene aldehydes (+)-albicanal 52 and (−)-albicanal 61 
(Scheme 9) [210,211]. The sesquiterpene quinone hyatellaquinone has been isolated from the alga 
Peyssonnelia  sp. and the marine sponges Hyatella intestinalis  [212] and Spongia  sp. [211]. 
Spongiaquinone  60  has been obtained from the sponges Spongia  sp. [211] and Stelospongia  
conulata  [213].  These terpenequinone were attractive candidates for pharmacological  testing as 
antitumor, HIV-1 reverse transcriptase inhibitor and immunomodulatory activities [72,142,208]. 
Scheme 9. Retrosynthesis of hyatellaquinone 58 and spongiaquinone 60. 
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The synthesis of (+)-hyatellaquinone 58 was achieved starting from the sesquiterpene aldehyde  
(+)-albicanal 52 (Scheme 10) [210]. Coupling of (+)-albicanal 52 with 2,3,5,6-tetramethoxyphenyllithium 
63 led to the aryl-sesquiterpene system 59, which was modified to the target molecule. Furthermore, 
the first total synthesis of spongiaquinone  60  was carried out starting from  (−)-albicanal  61  
(Scheme 11) [211] in a reaction sequence encompassing a stereoselective C=C bond hydrogenation 
and a one-pot AcOH elimination/demethylation reaction. 
Scheme 10. Synthesi of (+)-hyatellaquinone 58. 
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Siphonodictyal C 69, isolated from sponge Siphonodictyon  sp. [214,215], was tested for its 
pharmacological activities in assays in search of antiproliferative, cytotoxic, antiphlogistic, 
antirheumatic and anti-inflammatory drugs [70,208]. Synthesis of siphonodictyal C 69 was achieved 
via drim-7-en-11-al  70  by coupling with 5-lithium sesamol MEM-ether to the benzylic alcohols   
(±)-71a,b  (Scheme 12) [206,208]. Treatment of (±)-71a,b  with  p-toluene sulfonic acid (PTS) in 
THF/H2O led to the deprotection of the MEM-group and benzylic dehydration. The formed phenol 
was rearranged in a six membered cyclic transition state to the alkylidenecyclohexadienone which by 
reduction with NaBH4 in EtOH yielded the phenol that was deprotonated with n-Bu4NOH and the 
phenolate was methylated with dimethylsulfate (DMS), deprotonated with n-BuLi in o-position to the 
methoxy-group and formylated with DMF to (±)-72. The deprotection of (±)-72 with different reagents 
always led to decomposition.  Mar. Drugs 2012, 10                
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Scheme 11. Synthesis of (−)-spongiaquinone 60. 
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Scheme 12. Synthesis of protected siphonodictyal C 69 via drim-7-en-11-al 70. 
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In addition,  aureol  9  and their analogues were synthesized by coupling of the aldehydes with 
lithiated hydroquinone ethers using, in this case, a cis-decaline as starting material [216,217]. Aureol 
was isolated from the Caribbean sponges Smenospongia aurea [218] and Verongula gigantea [219].  
Aureol 9 has been shown to exhibit selective cytotoxicity against A-549 human non-small cell lung Mar. Drugs 2012, 10                
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cancer cells and antiinfluenza-A virus activity [67,220].  As shown  in Scheme  13, the synthesis 
commenced with the crucial coupling reaction of the cis-fused aldehyde [221,222] previously prepared 
from the enantiomerically pure (−)-Wieland-Miescher ketone 73 analogue (Figure 3) [223,224] with 
commercially available 2-bromoanisole.  
Figure 3. Wieland-Miescher Ketone 73. 
O O
(S)-(+)-73 (R)-(-)-73
O O
           
 
Scheme 13. Synthesis of (+)-arearone 80, (+)-arenarol 81 and (+)-aureol 9 staning from 
cis-fused decalin. 
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Thus, the aryllithium generated in situ by treatment of 2-bromoanisole with n-butyllithium in THF 
was allowed to react with 74  providing an excellent yield of the desired coupling product 75. 
Simultaneous removal of both the benzylic hydroxyl group and the ethylene acetal moiety in 75 was 
achieved effectively by initial formation of the corresponding trifluoroacetate 76 followed by reaction 
under  the conditions for hydrogenolysis, wich led to the production of the carbonyl group 77. 
Subsequent methylenation of the sterically hindered carbony group in 77 was achieved by employing 
the Takai procedure [225]. Thus, treatment of 77 with a mixture of dibromoethane, zinc powder and 
titanium (IV) chloride in THF furnished the exo-olefinic compound 78. The methylenation of 77 with 
Wittig reagent, Peterson’s reagent or Tebbe reagent gave none of desired product 78. Next, deprotection 
of the methyl ether protecting group of exo-olefin by treatment with lithium n-butylthiolate in 
hexamethyl-phosphoramide afforded the liberated phenolic compound 79. The pivotal conversion of 
the phenolic derivative to arenarone 80 was effected by reaction of 79 with molecular oxygen in the 
presence of salcomine in DMF. Subsequent reduction of the quinone system in arenarone 80 using 
sodium hydrosulfite gave arenarol  81.  By treating of arenarol with BF3·Et2O, the desired   
acid-promoted rearrangement/cyclation reaction was found to proceed, producing aureole 9 with a 
good stereoselectively in excellent yield [221,222]. 
Scheme 14.  Enantiospecific  synthesis of (+)-puupehenone  6. The arenol oxidative 
activation route. 
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The total synthesis of the (+)-puupehenone 6 was achieved in 10 steps (Scheme 14) by the arenol 
oxidative activation route  [153] starting from commercially available (+)-sclareolide  86. The key 
feature of this synthesis is the construction of the heterocycle via an intramolecular attack of the 
terpenoid-derived C-8 oxygen function onto an oxidatively activated 1,2-dihydroxyphenyl unit.   
The sequiterpene moiety of puupehenone  6  features a normal drimane skeleton annelated to a   Mar. Drugs 2012, 10                
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shikimate-derived hydroxyquinone unit. The drimane precursor (+)-sclarolide 86 already possesses the 
correct chirality for three of the four (+)-puupehenone 6 stereogenic centers. It can be purchased from 
commercial sources or convenientelly prepared from labdane 85 [226]. The nucleophilic character of 
the terpenoid 8-oxygen will serve to mediate the desired heterocyclization by attacking an oxidatively 
activated 1,2-dihydroxyphenyl unit. The shikimate unit 84 was elaborated from catechol 83 through 
bromination and benzylation to give bromide. Coupling of this bromide with aldehyde 87 obtained 
from (+)-sclarolide 86, was achieved via a standard halogen-metal exange protocol. A subsequent 
hydrogenolysis under standard conditions allowed removal of both benzyl protective groups, and the 
benzylic C-15 hydroxyl group that was unveiled at the previous coupling reaction, to afford the 
catechol 88 in good yield. The remarkable deprotection-deoxygenation step set the stage for the key 
oxidative activation of the catechol unit toward intramolecular attack by the drimane 8-oxygen. This 
activation relied on the use of [bis(trifluoroacetoxy)iodo]benzene (BTI), that as other iodine reagents, 
constitute today a convenient alternative to the use of toxic heavy metal-based reagents for activating 
arenols toward oxidative nucleophilic substitution reaction [227,228]. 
The synthesis of peyssonol A 90 is a special case of fusion between a cis-decalin and the aryl  
ring [229]. Peissonol A was isolated from the Red Sea marine alga Peyssonnelia sp. that has been 
shown to act as an allosteric inhibitor of the reverse transcriptases of Human Immunodeficiency   
Virus [212,230]. This compound is the only known natural product possessing a cis-decalin framework 
likely arising from a  halonium-induced cation-π  cyclization. As indicated in Scheme 15, the 
retrosynthetic analysis suggested that the late-stage disconnection on the pendant aryl ring projecting a 
nucleophilic addition onto the aldehyde 92 to effect its incorporation, might afford the most efficient 
means to reach a suitable polyene cyclization precursor. 
Scheme 15. Retrosynthetic analysis of peyssonol A 90. 
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5. Radical Decarboxylation and Quinone Addition Reaction 
The application of the Barton’s radical decarboxylation reaction, in which the generated radicals are 
trapped by a quinone trap, gives rise to addition products in good to excellent yields. This addition Mar. Drugs 2012, 10                
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reaction is characterized by good chemoselectivity, taking place only at conjugated and unsubstituted 
double bonds, and regioselectivity, being strongly influenced by the resonance effect of heteroatoms 
located on the quinone ring. The synthetic value of this reaction was demonstrated by the synthesis of 
selected members of a family of quinone sesquiterpenes. Both symmetric and unsymmetric quinones 
can be used as radical traps and provide facile access to heteroatom-substituted quinone sesquiterpenes. 
The versatility of our strategy was further expanded by developing reaction conditions that allow 
subsequent oxygenation of the  quinone adducts, providing access to complementary oxygenated 
structures [231].  
Essential to this strategy is a radical  addition  reaction that permits the attachment of a fully 
substituted bicyclic core 97 to a variably substituted p-quinone 98 (Scheme 16). The addition product 
96 can be further functionalized, giving access to natural products with a high degree of oxygenation at 
the quinone unit. The quinone addition reaction is characterized by excellent chemoselectivity, taking 
place only at conjugated and unsubstituted double  bonds, and regioselectivity, being strongly 
influenced by the resonance effect of heteroatoms located on the quinone ring. These features were 
successfully applied to the synthesis of avarol 1, avarone 2, ilimaquinone 3 and smenospongidine 116, 
thereby demonstrating the synthetic value of this method [231]. 
Scheme 16. Strategic bond disconnections of quinone sesquiterpenes. 
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Avarol 1 and its quinone derivative avarone 2 are secondary metabolites isolated from the marine 
sponge Dysidea avara [232,233]. Both compounds were first discovered as anti-leukaemia agents  
in vitro and in vivo, and later it was found that they had an in vitro inhibitory capacity against HIV-1. 
Controlled clinical studies revealed, however, that it was not efficient in the clinical treatment of 
patients with AIDS. Additionally, the potent T-lymphotropic cytostatic activity shown by avarol 1, and 
its low toxicity in mice, its ability to cross the blood-brain barrier and its ability to stimulate the 
synthesis of interferon make both these compounds optimum candidates for transformations aimed at 
improving their cytostatic and antiviral activity [234–238].  Mar. Drugs 2012, 10                
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Scheme 17. Total synthesis of avarol 1  and avarone 2 via radical decarboxyation and 
quinone addition reaction. 
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The synthetic approach toward the core fragment of avarol and avarone (Scheme 17) began with 
enantimerically enriched enone 73 (Figure 3), which was readily available through a L-phenylalanine-
mediated asymmetric Robinson annulation [239].  The selective protection of the more basic C4 
carbonyl group followed by reductive alkylation of the enone functionality with allyl bromide afforded 
ketone 99. Conversion of ketone 99 to silyl ether 100 was accomplished via a sequence of three steps 
including ozonolysis of the terminal double bond, reduction of the resulting aldehyde, and selective 
silylation of the primary alcohol. The C8 ketone functionality that also suffered reduction during the 
above procedure was subsequently restored upon treatment with Dess-Martin periodinane  [240]. 
Functionalization of C8 stereocenter was achieved by Wittig olefination, followed by a Pd-catalyzed 
hydrogenation of the resulting exocyclic methylene unit, furnishing alcohol 102. Acid-catalyzed 
deprotection of the C4 ketal of 102 gave rise to ketone 103, which a second Witting methylenation 
provided the exocyclic alkene 104. The exocyclic double bond of 104 was isomerized to produce de 
most substituted alkene 105, wich after a two-step oxidation involoving Dess-Martin periodinane and 
sodium chlorite, produced the desired carboxylic acid 106. The stage was now set for the attachment of 
the aromatic residue on the decalin ring. This was accomplished by DCC-induced esterification of 106 
with commercially available 2-mercaptopyridine-N-oxide 108, which furnished the photolabile ester 
108. Light-induced decarboxylation of ester 108 in the presence of benzoquinone 21 produced the 
substituted quinone 110. At this point, brief treatment of 110 with Raney nickel produced synthetic 
avarol 1 in 84% yield. Consequently, avarone 2 was produced from 1 via heterogeneous oxidation  
with MnO2. 
Scheme 18. Total synthesis of ilimaquinone and smenospongidine. 
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One of the synthetic strategies to ilimaquinone  3  and smenospongidine 116  is also based   
on a radical decarboxylation and quinone addition methodology (Scheme 18) [231,241]. These Mar. Drugs 2012, 10                
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terpenoquinones were colleted from Hippospongia  sp. [224,242,243]. The cytotoxicity against the 
NCI-H460, HepG2, SF-268, MCF-7, HeLa, and HL-60 human tumour cell lines, the inhibitory effects 
on the maturation of starfish oocytes, and cell cycle arrest in the HepG2 cell line were evaluated [242]. 
The chemical structures of ilimaquinone  3  and smenospongidine  116  differ from those of   
avarone-like molecules at the position  of unsaturation of the decalin core and the additional 
oxygenation at the C21 center of the quinone ring. The application of radical decarboxylation and 
quinone addition methodology produces quinone 113 from reaction of thiohydroxamic acid derivative 
with  benzoquinone  21.  Functionalization of 113  to ilimaquinone 3  is achieved by exploiting the 
electronic effects of the residual thiopyridyl group. Finally, exposure of 3 to phenylethylamine under 
basic conditions afforded synthetic smenospongidine 116. 
Ent-halimic acid  117  is used as starting  material for the synthesis of aureole  (−)-9, 
neomammanuthaquinone  120,  smenoqualone  121, and cyclosmenospongine  122. The Barton 
decarboxylation in presence of benzoquinone is the key reaction in this synthesis (Scheme 19) [244]. 
Scheme 19. Retrosynthetic analysis of some sesquiterpenequinones/hydroquinones from 
ent-halimic acid. 
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6. Grignard Reagent Conjugated Addition to α,β-Unsaturated Carbonyl Group 
The total synthesis of (±)-zonarol 47, (±)-isozonarol 49 [205,206] and (−)-yahazunol 45 [207,208] 
also were achieved by Grignard reagent (1,4) conjugated addition to α,β-unsaturated carbonyl group 
(Schemes 20 and 21) [245]. Mar. Drugs 2012, 10                
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Scheme 20. Synthesis of yahazunol 45 by Grignard reagent conjugated 1,4-addition to 
enone 12-nordrim-9-dn-8-one. 
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The synthesis of yahazunol 45  started from (+)-11-hydroxy-12-nordriman-8-one  123  which  
was transformed with p-toluene sulfonic acid by elimination of water to enone (+)-124. The   
cuprate catalyzed conjugated 1,4-addition of 2,4-dibenzyloxyphenylmagnesium bromide to   
(+)-12-nordrim-9-en-8-one (+)-124 yielded the enolate anion which was trappe with acetic anhydride. 
Treatment of the resulting enolacetate (−)-125 with potassium hydroxide in methanol afforded the Mar. Drugs 2012, 10                
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ketone  (+)-126. Wittig reaction of (+)-126  with PH3PCH2  gave (+)-zonarol dibenzyl ether   
(+)-127. Epoxidation in position 8–12 gave the oxirane ring which was opened with LiAlH4  to  
(+)-yahazunol dibenzyl ether. Debenzylation of (+)-10 with H2 and Pd/C yielded (−)-yahazunol 45 
(Scheme 20) [245]. 
In the synthesis of (±)-zonarol 47 and (±)-isozonarol 49 (Scheme 21), the terpene ketone 128, was 
prepared following a sequence of reactions [246] from the racemic mixture of the Wieland-Miescher 
ketone  73  (Figure  3).  This ketone  and its analogs are  of great interest as  starting materials  to 
terpenequinones by asymmetric synthesis [223,224,239]. After preparing the Grignard reagent 129, 
which provides the hydroquinone moiety, it was reacted with the α,β-unsaturated ketone 128, and 
Ac2O, yielding the enol acetate obtained by conjugate addition. Treatment of the enol acetate with 
KOH gave ketone 130, which established the stereochemistry of the molecule. From compound 130, 
(±)-zonarol 47 and (±)-isozonarol 49, were obtained by two different ways. Wittig reaction, followed 
by demethylation, zonarol racemate 6 was obtained. By 1,2-addition of organolithium to the ketone 
130, (±)-isozonarol 49 was obtained through a tertiary alcohol, which by dehydration gave a mixture 
of compounds 131 and 132. Finally, the demethylation of the methoxy group by treatment with lithium 
butanetiolate and HMPA led to (±)-zonarol 47 and (±)-isozonarol 49. 
7. Reductive Alkylation of Enones 
This strategy to connect the unit to a terpene quinone is based on the alkylation in the reaction 
medium during metal reduction of a conjugated double bond. Lithium with a solvent proton reduces 
the double bond through electron transfer giving an enolate. Thus, alkyl halide reaction generates the 
desired alkylated ketone. In all cases, the α,β-unsaturated ketone that is coupled to the quinone has the 
(S)-(+)-Wieland-Miescher diketone 73 as the starting material.  
The synthesis of (+)-avarone 2, (+)-avarol 1, (−)-neoavarone, 134 (−)-neovarol 133 and (+)-aureol 9 
is  a good example of reductive  alkylation  of enones  with bromides  (Scheme 22)  [247]. Thus,   
the enone 139  with bromide 140,  and  applying previously described protocols from the  
literature [156,239,248–251] gave the exo-olefin 138. The endo-olefin 136 should be accessible from 
138 by isomerization at the C4 olefinic double bond. 
The synthesis of the decalin derivative 138  (Scheme 23), a common key intermediate for the 
synthesis of (+)-avarone  2, (+)-avarol  1,  (−)-neoavarone  134,  (−)-neovarol  133  and (+)-aureol  9, 
started with the reductive alkylation of enantiomerically pure enone 139 with 2-methoxybromide 140. 
Thus, treatment of enone 139  with lithium metal in liquid ammonia followed by reaction of the 
intermediary lithium enolate with bromide 140 provided the expected coupling product 141 as a simple 
diastereomer. Subsequent methylenation of the sterically hindered carbonyl group in 141 was achieved 
by employing a combination of Ph3P+CH3Br- and t-BuOK furnishing the exo-olefin. To establish the 
C8 sterogenic center, the ethylene acetal moiety was first removed by acid treatment and the resulting 
ketone 142 was subjected to hydrogenation, which afforded the product 143 and its C8 epimer 144 
after separation by coumn chromatography on silica gel. Finally, compound 144  was efficiently 
converted to the desired key intermediate 138 by Wittig methylenation [247]. Mar. Drugs 2012, 10                
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Scheme 22.  Synthetic plan for (+)-avarone  2, (+)-avarol  1,  (−)-neoavarone  134,  
(−)-neovarol 133 and (+)-aureol 9 by enones reductive alkylation. 
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Scheme 23. Synthesys of key intermediate 138. 
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The  Scheme  24  shows  the synthesis of avarol  1  and avarone 2  from key intermediate 138. 
Isomerization of the exo-olefin moiety in 138 to endo-olefinic double bond was efficienthly achieved 
by treatment with RhCl3·3H2O. The endo-olefin 145 was then converted to avarone 2 and avarol 1 via 
phenol 146. To construct the quinone system directly, phenol 146 was allowed to react with molecular 
oxygen in the presence of salcomine, producing (+)-avarone 2. Subsequent treatment of avarone 2 with 
NaBH4 in THF/H2O resulted in the quinol avarol 1 [247]. 
Ilimaquinone 3 [224,242] and nakijiquinones 4, 163–165 [252–257] have also been synthesized 
using this strategy. In the synthesis of (−)-ilimaquinone 3 (Scheme 25) [250,251], compound 147 was 
treated with Li/NH3 giving the lithium enolate and subsequent treatment with benzyl halide 148 led to 
the α-alkylation product 149. The configuration of the remaining stereocenter (C-8) was established 
with a Wittig reaction followed by hydrogenation to yield compound 151 and its diastereomers (3:1). 
The oxidation of alcohol at C-4 and subsequent formation of the olefin led to 153. Finally, treatment 
with CAN and Pd (0) in basic medium, yielded (−)-ilimaquinone 3. Mar. Drugs 2012, 10                
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Scheme 24. Synthesis of avarol 1 and avarone 2 reductive alkylation of enones. 
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Scheme 25. Synthesis of ilimaquinone 3 by reductive alkylation of enones. 
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The reductive alkylation as strategy for building sesquiterpenilquinones has also been used in the 
synthesis of nakijiquinones [156,252]. From extracts of sponges from the family Spongiidae, collected 
in Okinawa several nakijiquinones were isolated. Nakijikinones are terpenequinones with an amino Mar. Drugs 2012, 10                
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acid  on  the  benzoquinone  ring  [253–257].  The HER2/Neu receptor tyrosine kinase is hugely 
overexpressed in about 30% of primary breast, ovary, and gastric carcinomas. Nakijiquinones are the 
only naturally occurring inhibitors of this important oncogene, and structural analogues of nakijiquinones 
may display inhibitory properties against another tyrosine kinase receptor involved in cell signaling 
and proliferation [156]. The synthetic route (Scheme 26), was optimized to obtain nakijiquinone C, 
using as intermediate  the  isospongiaquinone  162  and  later  the  strategy  was extended  to obtain 
nakijiquinones A–D 4, 163–165. 
Scheme 26. Synthesis of isospongiaquinone and nakijiquinone A–D 4, 163–165 by reductive 
alkylation of enones. 
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8. Cross-Coupling Reaction 
This strategy consists on the application of a (dppf)NiCl2-mediated neopentyl coupling in natural 
product synthesis and emphasizes the attractive combination of hydroxyl-directed hydrogenation to 
control stereochemistry followed by a neopentyl coupling to elaborate the carbon skeleton. 
Retrosynthetic analysis as summarized in Scheme 27 readily dissects arenarol to a neopentyl iodide 
166 and 2,4-dimethoxyphenylmagnesium bromide [258]. The neopentyl iodide turn could be derived 
from the corresponding alcohol 167, assuming that the hydroxyl group could be employed to control 
the stereochemistry of reduction at an adjacent exocyclic  olefin, or the diene alcohol 169, if the 
hydroxyl group could be employed to fix both adjacent stereocenters. Either olefin could be viewed as 
a derivative of the decalin 168, depending on the sequence employed to accomplish methylation, 
introduction of the exocyclic olefin, and for compound 168, reduction of the endocyclic olefin. The 
synthesis of arenarol, based  on  this approach, includes both directed introduction of two  key 
stereogenic centers and a (dppf)NiCl2-mediated coupling at a neopentyl center. 
Scheme 27. Retrosynthetic analysis of arenarol 81. 
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Arenarol  81, isolated from Dysidea  sp.  and  Fenestraspongia  sp. [259,260]  is a cis-decalin  the 
synthesis of which calls for stereocontrol at two tertiary and two quaternary carbons. These compounds 
showed cytotoxic activity when assayed against P-388 leukaemia cells, with ED50 = 17.5 μg/mL for 
arenarol  81  and ED50  = 1.7 μg/mL for arenarone 80  [259]. Arenarol 81  showed DPPH radical 
scavenging activity with an IC50 value of 19 μM [260]. The Grignard reagent needed for preparation  
of arenarol  81,  (2,5-dimethoxyphenyl)magnesium bromide 129, has been shown to undergo a   
cross-coupling reaction with neopentyl iodide in the presence of (dppf)NiCl2 and Zn2 dioxane forming 
the desired coupling product 171. Conversion of 171 to the target compounds required cleavage of the 
methyl protecting groups. Treatment of compound 171 with ceric ammonium nitrate (CAN) resulted in 
oxidation to the natural product arenarone 80. Mild reduction of arenarone 80 with Na2S2O4 gave the 
final target arenarol 81 (Scheme 28). Mar. Drugs 2012, 10                
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Scheme 28. Synthesis of arenarone 80 and arenatol 81 by cross-coupling reaction. 
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9. Furylation of Quinones 
This procedure consists on furylation of quinones and hydroquinones through oxidative coupling 
and Michael addition reactions. Thus, the oxidative coupling  reaction of (+) euryfuran with   
1,4-quinones in acetic acid yielded euryfuryl-1,4-quinones with leishmanicidal activity. The influence 
of the solvent to promote the Michael addition and the regioselectivity of the reaction with 
unsymmetrical quinones are important feactures that can be useful for the synthesis of new bioactive 
members of the euryfurylquinones series [261] (Scheme 29). The Michael reaction of (+) euryfuran 
172  with activated monosubstituted 1,4-benzoquinones  22  provides a regiospecific access to 
antiprotozoal active euryfuran derivatives 173 containinig a quinone or hydroquinone fragment bond to 
the  12 position [262].  Access to furylnaphthoquinones from unactivated quinones requires   
acid-induced conditions. However, oxidative coupling reactions of activate quinones proceed under 
neutral conditions. Most of the furyl-1,4-quinones exhibited good antiproliferative activity against 
MCF-7, NCI-H460 and SF-268 cancer cell lines [145]. 
Scheme 29. Furylation of quinones. 
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10. Furan Polyene Cationic Cyclization 
This strategy  is a diversity-oriented synthesis that follows a biomimetic route [263] to marine 
natural products like liphagal 1, the first member of a new of new liphagane type of meroterpenoid 
carbon skeleton. Liphagal 180 isolated from the methanol extract of the sponge Aka coralliphaga, 
collected from reefs in Prince Rupert Bay, Portsmouth, Dominica [264] exhibited impressive biological 
activity including inhibitory activity against PI3K a (phosphoinositide-3-kinase α) and cytotoxic to 
LoVo and CaCo human colon, and MDA-468 human breast tumor cell lines [264–266].  
Scheme 30. Synthesis of meroterpenoid natural product (±)-liphagal 180 Retrosynthetic 
analysis by furan polyene cationic cyclization. 
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Liphagal 180 has a tetracyclic skeleton, harboring a trans-fused 6,7-bicarbocyclic core with three 
stereogenic centers. The retrosynthetic strategy  toward liphagal  (Scheme 30)  was based on the 
proposed biogenetic pathway and hinged on a key C–C bond disconnection that mandated connecting 
a preformed benzofuran precursor 178 with a readily available monoterpenoid 177 to establish the 
crucial C–C bond and access the framework 8. Further elaboration of 176 into 175 was envisaged to 
set up the furan polyene cationic cyclization cascade en route to the target.The key furan precursor 178 
was to be ascessed from a readily available aromatic precursor 179. 
11. Application of Cell Culture for the Production of Bioactive Compounds from Sponges 
Sponges [phylum Porifera] are a rich source of biologically active and pharmacologically valuable 
compounds with a high potential to become effective drugs for therapeutic use. However, until now, 
only a few compounds have been introduced into clinics because of the limited amounts of starting 
material available for extraction. To overcome this serious problem in line with the rules for a Mar. Drugs 2012, 10                
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sustainable use of marine resources, the following routes can be pursued; first, chemical synthesis, 
second, cultivation of sponges in the sea (mariculture), third, growth of sponge specimens in a 
bioreactor, and fourth, cultivation of sponge cells in vitro in a bioreactor [267]. 
Recently,  it was demonstrated  that the in vitro  culture of  primmorph from the marine sponge 
Dysidea avara produces avarol 1. Single cells apparently do not have the potency to produce this 
secondary metabolite, but the primmorph model is a suitable system for the synthesis of bioactive 
compounds  in vitro [268,269].  In addition, it has also been  suggested that  some of the bioactive 
secondary metabolites isolated from sponges are produced by functional enzyme clusters, which 
originated from the sponges and their associated microorganisms. In order to exploit the bioactive 
potential of both the sponge and the “symbionts”, a 3D-aggregate primmorph culture system was 
studied, and it was proved that avarol/avarone is produced by the sponge Dysidea avara. Another 
promising way to utilize the bioactive potential of the microorganisms is the cloning and heterologous 
expression of enzymes involved in secondary metabolism [270]. 
In situ sponge aquaculture is nowadays one of the most reliable methods to supply pharmaceutical 
companies with sufficient quantities of the target compound. Its use in addition to immortalization of 
sponge cells by transfection with genomic DNA appears to be a promising way, since recent studies 
underscore the applicability of this technique for sponges [270]. 
12. Summary 
Sesquiterpenequinones represent a substance class with increasing pharmacological interest. The 
initial concentration of an interesting compound may be too low to be effectively tested in some 
biological and pharmacological assays. Thus, the  total synthesis  of  terpenequinones  has  become 
attractive in order to obtain the required amounts of  compounds natural product  analogues with 
optimized biological properties. Consequently, the development of these marine natural products is 
highly desirable and worthwhile from the viewpoint of medicinal chemistry and pharmaceuticals. 
Therefore, total synthesis of natural products will surely continue to be central to confirmation of 
natural product structure assignment, as well as providing material for biological testing towards 
pharmaceutical development, and investigations of biosynthetic pathways.  
The main routes to synthesize terpenequinones/hydroquinones include Diels-Alder cycloaddition 
reaction, coupling of the aldehydes with lithiated hydroquinone ether, radical decarboxylation and 
quinone addition reaction, Grignard reagent conjugated addition to α,β-unsaturated carbonyl group, 
reductive alkylation, cross-coupling reaction, furylation of quinones and furan polyene cationic 
cyclization. In addition, the application of cell culture for the production of bioactive compound from 
sponge is a promising way to utilize the bioactive potential of marine terpenoquinones sources. 
Advances in total synthesis, especially function-oriented synthesis,  biosynthetic technologies, 
primmorph models and genomic research offer new strategies for the medicinal chemical optimization 
of biologically active terpenequinones/hydroquinones.  
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